Abbott (NYSE:ABT) today unveiled a new initiative addressing the biases and stigmas associated with diabetes management. The maker of the leading FreeStyle Libre continuous glucose monitor (CGM) platform launched the “Above the Bias” initiative after a new survey highlighted how everyday comments centered around food, appearances and other stigmas may affect people living with diabetes. […]
abbott
Abbott Diabetes spurs growth with 22.7% uptick in CGM revenue, expects more insulin pump connectivity
Abbott (NYSE:ABT) today highlighted significant growth within its Diabetes business amid its fourth-quarter results for 2024. The company’s medical device business saw a 13.7% overall increase in sales, with double-digit growth both in the U.S. and abroad. Abbott pointed to a number of products contributing to the performance, including the FreeStyle Libre continuous glucose monitor […]
Abbott, Dexcom settle global CGM patent litigation
Abbott (NYSE:ABT) announced today that it reached an agreement with Dexcom (Nasdaq:DXCM) to settle all outstanding patent disputes between companies. The patent litigation relates to the companies’ continuous glucose monitor (CGM) technologies. Abbott and Dexcom are two leaders in the CGM space. They offer market-leading platforms, with Abbott’s FreeStyle Libre 3 and Dexcom’s G7 representing […]
The 5 most-read Drug Delivery Business News stories of 2024
There has been no shortage of news across the diabetes and drug delivery markets over the course of 2024. At Drug Delivery Business News, we’ve tried to cover it all. From product launches to major regulatory nods — with significant partnerships and integrations in between — diabetes technology particularly dominated the news over the last 12 […]
European court rules in favor of Abbott in Dexcom CGM patent spat
The Unified Patent Court in Paris sided with Abbott (NYSE:ABT) following a CGM patent infringement claim from Dexcom (Nasdaq:DXCM). Abbott and Dexcom are two leaders in the continuous glucose monitoring (CGM) space. They offer market-leading platforms, with Abbott’s FreeStyle Libre 3 and Dexcom’s G7 representing their latest-generation technologies. Dexcom requested that the court find infringement […]
Insulet Omnipod 5 is now compatible with Abbott FreeStyle Libre 2 Plus in the U.S.
Insulet (Nasdaq:PODD) today announced compatibility between its Omnipod 5 insulin pump and the Abbott (NYSE:ABT) FreeStyle Libre 2 Plus CGM in the U.S. The company says this latest integration makes Omnipod 5 the most connected tubeless automated insulin delivery system in the U.S. Compatibility in the U.S. comes about eight months after the company integrated […]
Abbott opens new FreeStyle Libre manufacturing plant in Ireland
Abbott (NYSE:ABT) announced today that it officially opened a new state-of-the-art manufacturing facility in Kilkenny, Ireland. The site serves as a global manufacturing center of excellence for Abbott’s Diabetes Care business. The company expects it to employ more than 800 people. Abbott announced its plans for the €440 million investment in Ireland in August 2022, then […]
The biggest diabetes tech stories of the year so far
On World Diabetes Day, it’s worth taking a look back at the last 10.5 months in the diabetes technology space. The date, which marks the birth date of the inventor of insulin, brings out all sorts of initiatives from various companies involved in innovating these technologies (read about those HERE). Those companies have contributed to […]
What diabetes tech companies are doing on World Diabetes Day 2024
World Diabetes Day — today, Nov. 14 — brings out the best in the diabetes community that continues to innovate year after year. This date serves as a time to recognize these innovations as it marks the birthday of Sir Frederick Banting. Banting discovered the insulin hormone along with Charles Herbert Best in 1922. The […]
Abbott reports sustained benefits with Esprit drug-eluting stent
Abbott (NYSE:ABT) today announced data demonstrating the long-term effectiveness of its Esprit BTK drug-eluting stent. The everolimus-eluting resorbable scaffold system treats chronic limb-threatening ischemia (CLTI) below the knee (BTK). Abbott designed it to keep arteries open and deliver everolimus to support vessel healing prior to completely dissolving. The first-of-its-kind stent provides support to the vessel […]
